Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4093/dmj.2016.40.2.99 http://scihub22266oqcxt.onion/10.4093/dmj.2016.40.2.99 C4853229!4853229!27126881     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Metab+J 2016 ; 40 (2): 99-114 Nephropedia Template TP {{tp|p=27126881|t=2016. An Update on the Effect of Incretin-Based Therapies on ?-Cell Function and Mass |pdf=|usr=}}{{27126881}} gab.com Text An Update on the Effect of Incretin-Based Therapies on -Cell Function and Mass JO: Diabetes Metab J http://www.kidney.de/pget.php?&tw=1&pmid=27126881 #FOAvip Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic ?-cell dysfunction and insulin resistance. Pancreatic ?-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve ?-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic ?-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on ?-cell function and ?-cell mass in animals and humans. Twit Text FOAVip An Update on the Effect of Incretin-Based Therapies on -Cell Function and Mass ????Diabetes Metab J http://www.kidney.de/pget.php?&tw=1&pmid=27126881 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27126881 #FOAvip English Wikipedia <ref>{{Cite pmid|27126881}}</ref> An Update on the Effect of Incretin-Based Therapies on ?-Cell Function and Mass #MMPMID27126881 Chon S; Gautier JF Diabetes Metab J 2016[Apr]; 40 (2): 99-114 PMID27126881show ga Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic ?-cell dysfunction and insulin resistance. Pancreatic ?-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve ?-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic ?-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on ?-cell function and ?-cell mass in animals and humans. äAn Update on the Effect of Incretin-Based Therapies on ?-Cell Function(epmc).pdf DeepDyve Pubget Overpricing